Table 4.

Projected undiscounted life expectancy and life-years gained with addition of ERN/LRPT 2 g in patients not at LDL-C goal on simvastatin monotherapy

	Scenario 1 (n = 707)		Scenario 2 (n = 886)
	Simvastatin 40 mg	ERN/LRPT 2 g + simvastatin 40 mg	Simvastatin 20 mg	Simvastatin 20 mg titrated to 40 mg	ERN/LRPT 2 g + simvastatin 20 mg
	Remaining life expectancy, years	LYG	Remaining life expectancy, years	LYG	LYG versus simvastatin 20 mg alone	LYG versus simvastatin up-titration
All patients	13.28	0.80	12.82	0.22	0.75	0.53
CHD without diabetes	14.13	0.73	13.63	0.21	0.70	0.49
CHD with diabetes	11.79	0.93	11.46	0.25	0.85	0.60
Age ≤65 years	17.62	1.25	17.75	0.37	1.22	0.86
Age >65 years	11.16	0.58	10.88	0.17	0.57	0.40
Low HDL-Ca	12.27	0.93	12.21	0.27	0.90	0.63
TC/HDL-C ratio ≥4.5	12.75	0.98	12.10	0.26	0.90	0.63

CHD Coronary heart disease, ERN extended-release niacin, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, LRPT laropiprant, LYG life-years gained, TC total cholesterol

^aLow HDL-C: men, <40 mg/dL; women, <45 mg/dL